| Faculty | Relationship Identified With: | |
| Roopen Arya | Speaker’s Bureau: Sanofi, Cardinal Health | |
| Fawaz Al-Mufti | Consultant: UCB, Stryker, Penunbra, Cerenovus, AstraZeneca | |
| Casey Albin, MD | Nothing to Disclose | |
| Sophia Ambruso | Consultant: AstraZeneca | |
| Dr. Sonia Anand | Consulting and speaker fees: Bayer AG, Janssen Pharmaceuticals | |
| Alessia Argirò | Nothing to Disclose | |
| Christos Argyropoulos MD, PhD, FASN | Consultant: Baxter Healthcare, Bayer | |
| Sara Azimi | Nothing to Disclose | |
| Christie Ballantyne, MD | Grant Research Support: Abbott Diagnostic, Akcea, Amgen, Arrowhead, Esperion, lonis, Novartis, Regeneron, Roche Diagnostic, NIH, AHA, ADA; Consultant- Abbott Diagnostics, Althera, Amarin, Amgen, Arrowhead, Astra Zeneca, Denka Seiken, Esperion, Genentech, Gilead, Illumina, Matinas BioPharma Inc, Merck, New Amsterdam, Novartis, Novo Nordisk, Pfizer, Regeneron, Roche Diagnostic, Sanofi-Synthelabo | |
| Geoffrey Barnes, MD, MSc | Consultant: Pfizer, Briston-Myers Squib, Janssen, Boston Scientific, Abbott Vascular; Board of Directors: Anticoagulation Forum | |
| Craig Beavers, PharmD, FACC, FAHA, FCCP, BCCP, BCPS-AQ Cardiology, CACP | Nothing to Disclose | |
| Sheila Bermejo García | Reports honorarium for conferences, consulting fees, and advisory boards from AstraZeneca, Boehringer and Mundipharma | |
| Deepak L. Bhatt, MD | Grant/Research Support: Abbott; Afimmune Limited; Amgen Inc.; AstraZeneca Pharmaceuticals; Bayer AG; Boehringer Ingelheim International GmbH; Bristol Myers Squibb; Cardax, Inc.; CHIESI USA, Inc.; CSL Behring; Eli Lilly and Company; Eisai Co., Ltd.; Ethicon; Ferring Pharmaceuticals; Forest Laboratories; Fractyl Laboratories, Inc.; Idorsia Pharmaceuticals Ltd; Ironwood Pharmaceuticals, Inc.; Ischemix; Lexicon Pharmaceuticals, Inc.; Medtronic; Pfizer; PhaseBio Pharmaceuticals, Inc.; PLx Pharma Inc.; Regeneron Pharmaceuticals; Sanofi; Synaptic, The Medicines Company | |
| Snehal H. Bhatt, PharmD | Speaker’s Bureau: Janssen Global Services, LLC | |
| Alexander J. Blood, MD, MSc | Sponsored research: General Electric Healthcare, Novo Nordisk, Boehringer Ingelheim; Consultant: Color Health, Walgreens Health; Strategy advisor: Arsenal Capital Partners; Advisor, equity holder: Knownwell Health | |
| Bryan Boling | Nothing to Disclose | |
| Allison E Burnett PharmD, PhC, CACP | Consultant: Abiomed | |
| Mauricio G. Cohen, MD | Consultant/Advisor: Abiomed; AstraZeneca Pharmaceuticals; Medtronic; Merit Medical Systems; Terumo Medical Corporation Speaker’s Bureau: Abiomed; Medtronic; Merit Medical Systems; Terumo Medical Corporation Ownership: Accumed Radial Systems | |
| A. John Camm | Consultant: Milestone, InCarda, Acesion, Huy Bio, Sanofi, Boston Scientific, Abbott, Medtronic | |
| Christopher P. Cannon, M.D. | Research Grants from: Amgen, Better Therapeutics, Boehringer-Ingelheim (BI), Daiichi Sankyo, Merck, Novo Nordisk, Pfizer; Consulting fees from Amryt/Chiesi, Alnylam, Amarin, Amgen, Applied Therapeutics, Ascendia, Biogen, BI, BMS, Eli Lilly, Janssen, Lexicon, Merck, Milestone, Pfizer, Rhoshan, Sanofi; Serves on the Data and Safety Monitoring Boards for the Applied Therapeutics, Areteia and Novo Nordisk. | |
| Dr. Marc Carrier, M.D., MSc, FRCPC | Consultant: Servier, BMS, Valeo, Sanofi, Anthos, Leo Pharma; Research Grant: Pfizer, Leo Pharma | |
| Clara García Carro | Travel and congress fees support from AstraZeneca, Esteve, NovoNordisk, Boehringer Ingelheim Lilly, Astellas, Otsuka, Novartis, Astellas, and Baxter; Scientific lectures, advisory boards and scientific committees organized by AstraZeneca, Boehringer Ingelheim Lilly, Mundipharma, Esteve and NovoNordisk | |
| Brooks D. Cash, MD | Consultant, Speakers’ Bureau: AstraZeneca, AbbVie, Ardelyx, Phathom; Speakers’ Bureau: Salix, Alynam, QOL | |
| Richard Choi DO | Nothing to disclose | |
| Ricardo Correa, MD | Nothing to disclose | |
| Jean Connors, MD | Consultant: Abbott; Alnylam; Speaker: Anthos Therapeutics; Roche; Sanofi; Data Safety Monitoring: Abbott; Bristol Myers Squibb; Pfizer; Werfen; Research Funding: CSL Behring | |
| Claire Davies | Speaker: NovoNordisk, CMM, Astra Zeneca, CareFlow Medicines Management, Diabetes Professional Care, NAPP; Advisor: MTech Access, Roche; Author: Green Light Pharmacy | |
| Melanie Davies CBE, MB ChB, MD, FRCP, FRCGP, FMedSci | Consultant, advisory board member, speaker and received grant: Boehringer Ingelheim, Eli Lilly, Novo Nordisk, Sanofi; Board Member: Lexicon, Pfizer, ShouTi Pharma Inc; Speaker: AstraZeneca, Napp Pharmaceuticals, Novartis, Janssen | |
| Tejas Desai | Nothing to disclose | |
| Dave L. Dixon, PharmaD | Research Funding: Boehringer Ingelheim | |
| Paul P. Dobesh, Pharm.D. | Consultant: The Pfizer/BMS Alliance, AstraZeneca Pharmaceuticals, Janssen Pharmaceuticals | |
| Thor Edvardsen | Nothing to disclose | |
| Gregory J. Fermann, MD, FACEP, FHFSA | Speaker’s Bureau: Astra Zeneca, Janssen; Research Support: Abbott Lab, Siemens, NIH; Advisory Board: Milestone Pharmaceuticals | |
| Kevin Fernando, MD | Consultant/Advisor: AstraZeneca Pharmaceuticals; Bayer AG; Boehringer Ingelheim International GmbH; Bristol Myers Squibb; Eli Lilly and Company; MSD Pharmaceuticals; NAPP Pharmaceuticals Limited; Novo Nordisk A/S; Sanofi Speaker’s Bureau: AstraZeneca Pharmaceuticals; Bayer AG; Boehringer Ingelheim International GmbH; Bristol Myers Squibb; Eli Lilly and Company; MSD Pharmaceuticals; NAPP Pharmaceuticals Limited; Novo Nordisk A/S; Sanofi; Daiichi Sankyo, Amgen & Amarin | |
| Ines Fonseca | Speaker, conference support: Novo Nordisk; Conference support: Lilly; Speaker: AstraZeneca | |
| Dr GIUSEPPE GALATI | Nothing to disclose | |
| Dr Robert P. Giugliano | Clinical Trials/Research Support: Amgen, Anthos Therapeutics, Daiichi Sankyo; Honoraria for Lectures / CME Programs: Amgen, Centrix, Daiichi Sankyo, Dr. Reddy’s Laboratories, Medical Education Resources (MER), Medscape, Menarini, Merck, Pfizer, SAJA Pharmaceuticals, Servier, Shanghai Medical Telescope, Voxmedia; Consultant: Amarin, Amgen, Boston Scientific, CryoLife S, CSLBehring, CVS Caremark, Daiichi Sankyo, Esperion, Gilead, Hengrui, Inari, Janssen, Novartis, Pfizer, PhaseBio Pharmaceuticals, St. Lukes, Samsung | |
| Shaun Goodman, MD | Consultant: Amgen; Anthos Therapeutics; AstraZeneca; Bayer; Boehringer Ingelheim; Bristol Myers Squibb; CSL Behring; Eli Lilly; Ferring Pharmaceuticals; HLS Therapeutics; JAMP Pharma; Novartis; Pendopharm/Pharmascience; Pfizer; Regeneron; Sanofi; Servier; Tolmar Pharmaceuticals; Valeo Pharma; Canadian Heart Research Centre and MD Primer; Speaker: Amgen; Anthos Therapeutics; AstraZeneca; Bayer; Boehringer Ingelheim; Bristol Myers Squibb; CSL Behring; Eli Lilly; Ferring Pharmaceuticals; HLS Therapeutics; JAMP Pharma; Novartis; Pendopharm/Pharmascience; Pfizer; Regeneron; Sanofi; Servier; Canadian Heart Research Centre and MD Primer; Steering Committee: Anthos Therapeutics; Bayer; Boehringer Ingelheim; Bristol Myers Squibb; CSL Behring; CYTE Ltd.; Esperion; Ferring Pharmaceuticals; Novartis; Pfizer; Regeneron; Sanofi; Cleveland Clinic Coordinating Centre for Clinical Research; Duke Clinical Research Institute; New York University Clinical Coordinating Centre; PERFUSE Research Institute; TIMI Study Group (Brigham Health); Data Safety Monitoring: Daiichi-Sankyo/American Regent; Novo Nordisk | |
| Dr. Ilana Halperin | Speaker, Consultant: Dexcom Canada, Sanofi; Speaker: Sanofi; Consultant: Abbott Diabetes Canada | |
| Will Herrington, MA, MBBS, MD, FRCP | Personal fellowship and institutional grant funding: Medical Research UK and Kidney Research UK. Research support: Boehringer Ingelheim and Lilly. I follow a departmental policy to decline any honoraria from the pharmaceutical or food industry. | |
| Mellanie True Hills, CSP | Nothing to disclose | |
| Dr. Patrick Holmes MB BS, MSc, DipTher, MRCGP | Consultant: AstraZeneca, NovoNordisk, Eli Lilly, Abbot; Speaker’s Bureau: AstraZeneca, Boehringer Ingelheim, NovoNordisk, Eli Lilly; Research Grant Recipient: NovoNordisk, Roche | |
| Diana Isaacs, PharmD, BCPS, BCACP, BC-ADM, CDCES, FADCES, FCCP | Speaker: Dexcom, Abbott, Novo Nordisk ; Consultant: Insulet, Lilly, Cequr, Medtronic, Sanofi | |
| Noah Ivers, MD, CCFP, PhD | Evaluation consulting and speakers fee: Novo Nordisk; Evaluation consulting: Merck | |
| Cynthia Jackevicius | Nothing to disclose | |
| Stefan James | Clinical Trial Steering Committee: AstraZeneca, Jansen, Bayer, Elixir; Consulting: Medtronic | |
| Sanjit Jolly | Institutional Research Grant: Boston Scientific; Consultant Fee: Medtronic | |
| Sergio Emanuel Kaiser, M.D., MSc, PhD, FACC, FESC | Speaker, Consultant, Investigator: Novo Nordisk; Speaker and Consultant: Astrazeneca; Speaker: Novartis, Bayer, Behringer Ingelheim, Merck Serono, Daiichi Sankyo | |
| Darae Ko, MD, MSc | Advisory Board: Eagle Pharmaceuticals, Inc; Research Grant: Boston Scientific Corp; Speaker: CME Outftters, LLC | |
| Mikhail Kosiborod, MD | Consultant/Advisor: Alnylam; Amgen Inc.; Applied Therapeutics; AstraZeneca Pharmaceuticals; Bayer AG; Boehringer Ingelheim International GmbH; Cytokinetics; Eli Lilly and Company; Janssen Global Services, LLC; Lexicon; Merck & Co., Inc. (Diabetes and Cardiovascular); Novo Nordisk A/S; Pharmacosmos; Sanofi; Vifor Pharma; Grant/Research Support: AstraZeneca Pharmaceuticals; Boehringer Ingelheim International GmbH | |
| Edgar V. Lerma | Speaker’s Bureau: AstraZeneca; Bayer; Otsuka Consultant: Vifor; Otsuka; Bayer | |
| Jane A. Linderbaum, MS APRN, CNP, FACC, FPCNA | Nothing to disclose | |
| Niels D. Martin, MD, FACS, FCCM | Consultant/Advisor/Speaker: AstraZeneca; Consultant: Nestle, FloBio | |
| Stephan A. Mayer, MD, FCCM, FNCS | Advisory Board: AstraZeneca | |
| Taher Modarressi, MD | Speakers’ Bureau: AstraZeneca | |
| Ahmad Masri | Research Grants: Pfizer, Akcea, Ionis, Ultromics; Honoraria: Pfizer, Alnylam, Eidos, Akcea, Ionis, Cytokinetics, BMS; Consultant: Attralus, Tenaya, Ionis | |
| Roxana Mehran, MD | Consultant/Advisor: Abbott; Boston Scientific; Bristol Myers Squibb; CardiaWave; CHIESI USA, Inc.; Concept Medical; CineMed; Daiichi Sankyo, Inc.; Idorsia Pharmaceuticals; Janssen Global Services, LLC; Medtronic; Medscape; Novartis AG; Regeneron Pharmaceuticals; Spectranetics/Philips/Volcano Corporation; WebMD Grant/Research Support: Abbott; Abiomed; Applied Therapeutics; AstraZeneca Pharmaceuticals; Bayer AG; Bristol Myers Squibb; Cerecor Inc; CHIESI USA, Inc.; Concept Medical; CSL Behring; Daiichi Sankyo, Inc.; Medtronic; Novartis AG; OrbusNeich; Zoll Medical Corporation Speaker’s Bureau: Boston Scientific; CineMed; Janssen Global Services, LLC; Medscape; WebMD Equity: Applied Therapeutics; Elixir Medical; STEL | |
| Erin D. Michos | Advisory Board: Novartis, Esperion, Amarin, AstraZeneca | |
| Dr Ahmed Mohsen, MD, MSc. | Nothing to disclose | |
| Nicholas Morris, M.D. | Nothing to disclose | |
| Rohit Moudgil, MD | Nothing to disclose | |
| Denisa Muraru | Speaker: GE Healthcare, Philips Medical Systems. | |
| James Novak, MD PhD FASN FNKF FACP | Nothing to disclose | |
| Katelyn O’Brien, PharmD, BCPS, CDCES | Nothing to disclose | |
| Iacopo Olivotto | Consultant: BMS, Cytokinetics, Amicus, Shire Takeda, Genzyme, Rocket Pharma, Tenaya | |
| Siddharth M. Patel, MD, MPH | Consultant: Janssen | |
| Fausto J Pinto | Consultant: Bayer, Boehringher Ingelheim, Daichii Sankyo, Novartis, Philips, Servier, Vifor | |
| Charles V. Pollack Jr., MD (Course Chair) | Grant/Research Support: AstraZeneca Pharmaceuticals, eXIthera Pharmaceuticals, Provepharm US; Consultant/Advisor: AstraZeneca Pharmaceuticals, eXIthera Pharmaceuticals, Provepharm US, PhaseBio Pharmaceuticals, orexo, VERO Biotech, Milestone Pharmaceuticals | |
| Richard Pratley, MD | Consultant/Advisor: Merck & Co., Inc.; Novo Nordisk A/S; Pfizer; Sanofi; SCOHIA PHARMA, Inc.; Sun Pharmaceutical Industries Ltd. Grant/Research Support: Hanmi Pharmaceutical Co.; Metavention; Novo Nordisk A/S; Poxel SA Speaker’s Bureau: Allergan; Novo Nordisk A/S | |
| Dr. Amar Puttanna | Speaker’s Bureau: Novo Nordisk, Lilly-Boehringer Ingelheim, Sanofi, Daiichi- Sankyo, AstraZeneca; Consulting: Sanofi | |
| Nataliya Pyslar, MD | Nothing to disclose | |
| Brian Rifkin, MD | Nothing to disclose | |
| Leyla Elif Sade | Nothing to disclose | |
| Katherine Sandquist | Nothing to disclose | |
| Naveed Sattar | Consulting/speaker honoraria: Abbott Laboratories, Afimmune, Amgen, AstraZeneca, Boehringer Ingelheim, Eli Lilly, Hanmi Pharmaceuticals, Janssen, MSD, Novartis, Novo Nordisk, Pfizer, Roche Diagnostics, Sanofi; Grants: AstraZeneca, Boehringer Ingelheim, Novartis, Roche Diagnostics | |
| Dr. Sanjiv Shah | Grant: National Institutes of Health, Actelion, AstraZeneca, Crovia, Novartis, Pfizer; Consultant: Abbott, Actelion, AstraZeneca, Amgen, Aria CV, Axon Therapies, Bayer, Boehringer-Ingelheim, Boston Scientific, Bristol-Myers Squibb, Cardiora, Coridea, CVRx, Cyclerion, Cytokinetics, Edwards Lifesciences, Eidos, Eisai, Imara, Impulse Dynamics, GSK, Intellia, Ionis, Ironwood, Lilly, Merk, MyoKardia, Novartis, Novo Nordisk, Pfizer, Prothena, Regeneron, Rivus, Sanofi, Sardacor, Shifamed, Tenax, Tenaya, United Theraputics | |
| Ashkan Shoamanesh, MD, FRCPC, FESO | Consultant/Research Funding: Bayer AG, Daiichi Sankyo Ltd., Servier Canada; Consultant: Bioxodes, AstraZeneca, Takeda Pharmaceuticals | |
| Pam R. Taub, MD, FACC, FAPSC | Consultant: Amgen, Medtronic, Bayer, Boehringer Ingelheim, Esperion, Novartis, Novo Nordisk, Amarin | |
| Dr. Ritu Thamman | Consultant: Bayer | |
| Paul D. Thompson, MD | Consultant: Amgen, Regeneron, Esperion, and Sanofi; Research Support: Sanofi, Regeneron, Esperion, Amarin, Norvartis and Pfizer; Owns Stock: Abbvie, Abbott Labs, CVS, General Electric, Johnson & Johnson, Medtronic, and Sarepta; Provided Legal Consultation on exercise-related cardiac events and statin myopathy | |
| Carlo Nemesio Trinidad, MD, FPCP, FPSN | Speaker: AstraZeneca; Corbridge Philippines; Otsuka; Sanofi | |
| Hartzell V. Schaff | Nothing to disclose | |
| Diego Segura-Rodriguez | Novartis, Astrazeneca, Boehringer-Lilly, Bayer, Rovi | |
| Dr Sourabh Sharma | Nothing to disclose | |
| Deborah Siegal MD MSc FRCPC | Honoraria: BMS-Pfizer, Leo Pharma, Servier | |
| Brett W Sperry, MD | Speaker: Pfizer; Advisor: Alnylam, BridgeBio, AstraZeneca | |
| Natalie Staplin, PhD | Research funding paid to institution for EMPA-KIDNEY trial: Boehringer Ingleheim; Eli Lilly and Company. Research funding paid to institution ASCEND-PLUS trial: Novo Nordisk. | |
| Alex C. Spyropoulos, MD, FACP, FCCP, FRCPC | Research Funding/ Consultant: Janssen; Consultant: Bristol Myers Squibb, Boehringer Ingelheim, Atlas Group, Alexion, Bayer | |
| James A. Underberg, MD | Consultant/Advisor: Amgen Inc.; Esperion Therapeutics, Inc.; Grant/Research Support: Amryt Pharma plc; Speaker’s Bureau: Ambry Genetics; Amgen Inc.; Amryt Pharma plc; GBIinsight; Novartis AG; Regeneron Pharmaceuticals Inc | |
| Dr. Alfonso Valle, MD, PhD | Nothing to disclose | |
| Dr. Harriette Van Spall | Research Funding: Canadian Institutes of Health Research, Heart and Stroke Foundation of Canada | |
| Prof. Dr. Frederik H. Verbrugge | Consultant: AstraZeneca, Bayer, Boehringer Ingelheim, Bristol-Myers Squibb Belgium, Roche Diagnostics, Qompium; Speaker: Abiomed, AstraZeneca, Bayer, Boehringer Ingelheim, Bristol-Myers Squibb Belgium, Menarini Group, Novartis Pharma, Novo Nordisk, Pfizer, Qompium; Institution received grants: Roche Diagnostics; Travel grants: Abbott Laboratories, Bayer, Novo Nordisk, Pfizer | |
| Tzu-Fei Wang, MD, MPH | Research funding: Leo Pharma; Advisory honorarium: Valeo | |
| Jason Weatherald, MD | Advisory board participant: Acceleron; Advisory board participant, speaker’s bureau, research grant recipient: Janssen/Actelion; Shareholder: Precision Lung Consultants & Diagnostics; Clinical Trial investigator: Merck | |
| Patricia Wedge, RN, BSN, CCRC | Nothing to Disclose | |
| Susan Weiner, MS, RDN, CDCES, FADCES | Nothing to Disclose | |
| Jeffrey Weitz, MD | Consultant: Alnylam; Anthos Therapeutics; Bayer; Boehringer Ingelheim; Bristol Myers Squibb; Daiichi-Sankyo; Ionis; Janssen; Merck; Novartis; Pfizer; Regeneron; Servier Scientific Advisory Board: Alnylam; Anthos; Bayer; Boehringer Ingelheim; Bristol-Myers Squibb; Daiichi-Sankyo; Ionis; Janssen; Merck; Novartis; Pfizer; Regeneron; Servier Research Support/P.I.: Canadian Institutes of Health Research; Heart and Stroke Foundation;Canadian Fund for Innovation | |
| Ronald Witteles, MD | Advisory Board participant: Novo Nordisk, Ionis, Astra Zeneca, BridgeBio, Alexion; Consultant: Alnylam; Speaker: Pfizer |
All relevant financial relationships with ineligible companies for this educational content have been mitigated.